In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Engaging minority communities: collaborative practises and long-term success
Rare diseases can disproportionately affect minorities, yet these communities are often underrepresented in clinical studies. ICON’s experts suggest ways to improve engagement and diversity.
-
Human-enabled AI driving enhancements in clinical trial site selection
In this piece from Clinical Trial Vanguard, Travis Caudill, Vice President, Feasibility, Site Identification & Clinical Informatics explores the improvements in site selection that human-enabled AI is delivering.
-
Pharma’s obsession with obesity on rise
ICON experts, Jack Martin and Simon Bruce share insights with BioSpectrum Asia on emerging trends in obesity treatment and the future implications for pharma.
-
Building on biotech confidence with strategic R&D
In this article from BIO-IT World, Dr. Chris Smyth, President of ICON Biotech outlines how despite ongoing challenges, biotech companies can build on growing market confidence by utilising their capital in the most effective and efficient way possible, through improved trial designs, timelines and data-responsive strategies.
-
Pivoting toward sustainable supply chains in clinical research
In this article from Applied Clinical Trials, Kelly Corkey, Director, Clinical Supplies Management, IRT and Leonard Wee, VP, Global Supply Chain, Laboratories outline how by adopting a holistic approach that optimises each component of the process, the clinical research industry can collectively drive progress and pivot toward a greener future while continuing to support patient-centred clinical research.
-
Navigating shifting paradigms in dose optimisation and dose selection for oncology therapeutics
In this article, ICON expert, Tim Clark, discuss the shift in paradigms in dose optimisation and dose selection for oncology therapeutics.
-
Innovations contributing to the re-emergence of antibody drug conjugates
“ADCs are emerging as one of the fastest-growing segments of pharmaceuticals in 2024, the number of FDA approvals are likely to accelerate, revealing new treatment pathways and new problems to solve along the way.” Learn more in this article with the Clinical Oncologist Daily.
-
Leveraging Healthcare Intelligence to increase diversity of oncology clinical trials
This article in the Clinical Oncologist Daily, provides as overview on leveraging healthcare intelligence to increase diversity of oncology clinical trials.
-
Navigating oncology development decisions for long-term success
In this media article, ICON expert Tanja Obradovic, PhD, highlights how mapping clear inflection points for data-driven decisions will inform efficient drug development.
-
Paediatric clinical trials for obesity treatment
In this article, ICON experts Alan Baldridge and Heather Peterson discuss the prevalence of paediatric obesity and assess clinical trials of its treatments.
